Based on previous findings that combination targeting of S6K1 and AXL effectively reduced viability of PTEN-deficient GBM, we initiated preclinical therapeutic studies by testing inhibitor effects on tumor growth in nude mice that were injected subcutaneously with PTEN-deficient GBM U87MG (27). This evidence concerns the gene PTEN and neoplasm.